Buy U-47700 (Pink) is an opioid analgesic drug developed by a team at Upjohn in the 1970s which has around 7.5 times the potency of morphine in animal models.
U-47700 is an opioid that is a structural isomer of an earlier opioid known as AH-7921. It was developed as a consequence of a significant amount of research into the quantitative structure–activity connection of the scaffold. Upjohn sought the key moieties that produced the most activity , and they filed over a dozen patents on similar compounds, with each patent optimizing a different moiety until they determined that U-47700 was the most active of the bunch.
U-47700 was selected as the lead molecule for the development of selective kappa-opioid receptor ligands such as U-50488, U-51754 (with a single methylene spacer variation), and U-69,593, all of which have extremely similar structural makeups.
The selective kappa ligands are used in research but are not utilized in any medicinal applications.
Our research compounds are, for the most part, structural or functional analogs of restricted substances. These analogs have been engineered to imitate the pharmacological effects of the original drug, but they are not unlawful and cannot be found in normal drug tests. The term “research chemicals” may refer to both psychoactive compounds and synthetic versions of medications that improve performance. Some of them were first produced by academic or industrial researchers to develop more effective derivatives with fewer adverse effects. Later on, these compounds were repurposed for usage in recreational activities. Other research substances were manufactured for the very first time in underground labs. Because the effectiveness and safety of these chemicals have not been adequately studied in animal and human studies, the use of some of these pharmaceuticals may result in unanticipated adverse consequences.
The creation of so-called “designer drugs” might be categorized as a subspecialty within the subject of drug design. The investigation of modifications to known active drugs, such as their structural analogs, stereoisomers, and derivatives, results in the production of drugs that may have effects that are significantly different from those of their “parent” drug (for example, showing increased potency or decreased side effects). In certain cases, designer medications exhibit the same effects as other pharmaceuticals that are already on the market but have entirely different molecular structures (for example, JWH-018 vs THC). In spite of the fact that it is a fairly general phrase that can be used for nearly any synthetic drug, it is often used to refer to synthetic medications that are taken for recreational purposes, and occasionally even ones that have not been developed at all (e.g. LSD, the psychedelic side effects of which were discovered unintentionally).